SH3TC2 and cancer: Next, we cross-analyzed the expression (Figure 1) and prognosis (Figures 2(a)–2(d)) of SH3TC2, and found that SH3TC2 was dysregulated in three cancers and significantly correlated with poor DFS in patients; they are COAD, PAAD, and READ (Figure 2(e)).